Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 299 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Osteoarthritis, Spine Clear all
Completed Not applicable Interventional

The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA)

NCT06072859
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Humidified Forest Oils, Forest oils and audio-visual forest exposure
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 14, 2026, 2:54 AM EDT
Withdrawn Phase 2 Interventional

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

NCT02429882
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Brodalumab 210 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Oklahoma City, Oklahoma • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 14, 2026, 2:54 AM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

NCT02798211
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab 300 mg, Secukinumab 150 mg, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 14, 2026, 2:54 AM EDT
Active, not recruiting No phase listed Observational

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

NCT02281747
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
20 Years to 100 Years
Enrollment
521,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 2:54 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Treatment With Apremilast in Patients With Psoriatic Arthritis

NCT02558361
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Treatment with Apremilast
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 14, 2026, 2:54 AM EDT
Withdrawn Phase 2 Interventional

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

NCT03488147
View directory record Official record
Conditions
Dysphagia, GERD, Degenerative Joint Disease
Interventions
Esomeprazole, Placebo Oral Tablet
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 14, 2026, 2:54 AM EDT
Completed No phase listed Observational

Treatment Goals in Psoriatic Arthritis

NCT03620188
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Standard of care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 95 Years
Enrollment
250 participants
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

NCT04169373
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 14, 2026, 2:54 AM EDT
Terminated Phase 2 Interventional

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

NCT04795141
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
ABY-035, Placebo
Drug
Lead sponsor
Inmagene LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Glendale, Arizona • Canoga Park, California • Huntington Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Decision-Framing in Psoriasis

NCT04136314
View directory record Official record
Conditions
Psoriasis Vulgaris, Psoriatic Arthritis, Psoriasis
Interventions
Decision-Framed Survey
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

NCT02963506
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, Bimekizumab
Other · Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Anniston, Alabama • La Jolla, California • Upland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 14, 2026, 2:54 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

NCT01009086
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Encinitas, California • La Jolla, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

NCT02538341
View directory record Official record
Conditions
Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
Interventions
Herpes Zoster (HZ) Vaccine, Placebo
Biological · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 14, 2026, 2:54 AM EDT
Recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Active Comparator, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 14, 2026, 2:54 AM EDT
Recruiting Not applicable Interventional

Evaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation

NCT06407427
View directory record Official record
Conditions
Spine Degeneration, Hip Arthritis, Knee Osteoarthritis, Hip Fractures
Interventions
App for in-bed conditioning exercises, Usual care
Device · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Phase 2 Interventional

A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis

NCT00001422
View directory record Official record
Conditions
Arthritis, Psoriatic, Psoriasis
Interventions
fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 2:54 AM EDT
Completed Not applicable Interventional Results available

Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

NCT01305356
View directory record Official record
Conditions
Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis, Rheumatoid Arthritis
Interventions
Augment® Injectable Bone Graft, Autologous bone graft
Device · Procedure
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Tucson, Arizona • San Francisco, California • Glenview, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 14, 2026, 2:54 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Fountain Valley, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 2:54 AM EDT
Withdrawn Phase 2 Interventional

Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis

NCT04115020
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 14, 2026, 2:54 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Glendale, Arizona • Mesa, Arizona • Jonesboro, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 2:54 AM EDT